COMPANY PROFILE

Tenvie Therapeutics

Explore full profile

Precision-designed small molecule therapies enhancing CNS penetration for diverse neurological diseases

San Francisco, United StatesFounded 2025Biotech & Life Sciences

Valuation $500M–1B Latest valuation · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Tenvie Therapeutics

Tenvie Therapeutics is dedicated to transforming the treatment landscape for neurological diseases through the development of precision-designed small molecule therapies. The company leverages its expertise in optimizing critical molecular delivery properties to enhance CNS penetration, thereby maximizing patient impact across a broad spectrum of conditions. Tenvie's business model focuses on a deep and diverse portfolio of small molecule assets, including programs acquired from Denali Therapeutics Inc. The company serves patients and caregivers, aiming to improve their lives with breakthrough therapies. Tenvie generates revenue by advancing its proprietary drug development pipeline, targeting unmet medical needs in the CNS domain. The leadership team, led by President and Chief Scientific Officer Tony Estrada, brings a proven track record in CNS drug development, ensuring a strategic approach to innovation and patient care. Keywords: CNS, small molecules, neurological diseases, drug development, molecular delivery, patient impact, Denali Therapeutics, precision therapies, revenue model, leadership.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2025
Headquarters: San Francisco, United States
Employees: 49
Open positions: 3
Dealroom signal: 92.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Tenvie Therapeutics.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Jan 2025	$200M	$800M	Mubadala Capital · ARCH Venture Partners · F-Prime	↗
CORPORATE SPINOUTOther financing	Jan 2025	$0	—	Denali Therapeutics	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Tenvie Therapeutics website traffic

Latest recorded traffic for Tenvie Therapeutics is 4.7K monthly website visits, up 327.3% over the last three months. Tenvie Therapeutics's team grew 104.2% over the past year.

Latest monthly visits4.7K 3-month web change+327.3% 1-year team growth+104.2%

Monthly website visitsJan 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EBEmalex BiosciencesA biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions	Chicago, United States	Acquired	48	$285M	$700M
TPTauRx PharmaceuticalsDeveloping tau aggregation inhibitors for neurodegenerative diseases	Aberdeen, United Kingdom	Operational
TTTRIMTECH TherapeuticsDeveloping small molecule degraders targeting protein aggregates for neurodegenerative and inflammatory disorders	Cambridge, United Kingdom	Operational
NTNeusignal TherapeuticsTherapeutic drugs for Central Nervous System diseases	Tokyo, Japan	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
APAdarx PharmaceuticalsProviding effective and safe therapeutics to patients who suffer from intractable diseases	San Diego, United States	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
BTBoruikang TechnologyBrain-computer interface and EEG systems used for neuroscience research and clinical neurological diagnosis	Haidian, China	Operational